Chicago Atlantic BDC · Nasdaq: LIEN
Chicago Atlantic BDC
Status: NotRated. Rating, target, reference quote and upside are null. Full valuation underwriting remains held.
Chicago Atlantic BDC, Inc. is an externally managed business development company whose Nasdaq common stock trades as LIEN. An SEC organization note records the October 1, 2024 acquisition and October 2 name-and-ticker change from Silver Spike Investment Corp. and SSIC. SSIC is therefore a historical listing alias, not a second issuer. The lender invests mainly in cannabis companies but may lend outside cannabis.
The June 30, 2026 Form 10-Q reported $343.96 million of assets, $41.47 million of liabilities and $302.49 million of net assets across 22.82 million shares, or $13.26 per share. Investments were carried at $334.83 million against $336.75 million of amortized cost, a 0.57% discount. Because this is an investment company, NAV and borrower-level recoveries are more relevant starting points than an operating-company EBITDA multiple.
Credit marks looked stable but are not conclusive. Grade 3 investments were $15.46 million, 4.62% of portfolio fair value; there were no reported grade 4 or 5 positions or non-accruals. First-half PIK interest of $2.74 million and discount or fee accretion of $1.95 million were recognized income rather than current cash collections. Collateral coverage, borrower liquidity and collectability therefore matter more than the absence of non-accrual labels. Reported portfolio yield also cannot substitute for realized loss history, concentration limits or security-priority analysis across individual borrowers.
The August 13 results filing reported second-quarter net investment income of $7.65 million. Against the $0.34 quarterly dividend and June share count, indicated dividend coverage was about 98.7%. This is a historical diagnostic, not forward guidance. Borrowings rose from $27.0 million at June 30 to $53.5 million on August 12, while disclosed liquidity was $47.2 million. The June capital base is therefore stale for a current target. Undrawn facility capacity is conditional funding, not cash, and should not be added to NAV.
A current SEC Form N-14 says the proposed merger with Chicago Atlantic Real Estate Finance remains subject to shareholder approvals and other closing conditions, with closing expected in the fourth quarter of 2026. Consideration is based on adjusted closing NAVs, so a March ownership estimate is not a fixed exchange ratio. REFI and LIEN remain separate research records until closing, and this review does not extend any opinion from one security to the other.
A rating requires final merger votes and closing terms, transaction expenses and waivers, a closing capital bridge, borrower cash-interest and PIK collection evidence, and collateral recovery work. Positive outcomes could include clean closing and durable cash collections. Falsifiers include borrower nonpayment, collateral shortfalls, adverse NAV adjustments, higher funding costs or fees eroding distributable income.
cbdMD · NYSE American: YCBD
cbdMD
NYSE American: YCBD · Initial review Status: NotRated · target, reference quote and upside withheld
Business and security identity
cbdMD, Inc. markets cannabinoid wellness and animal-health products and has expanded through acquisitions, including Bluebird Botanicals. The current common security is NYSE American YCBD. The former Series A preferred ticker YCBD.PA ceased trading after the issuer’s mandatory May 2025 conversion and is not treated as a current second listing.
Latest verified financial position
At June 30, 2026, cbdMD reported US$2.118 million of cash, US$7.697 million of current assets, US$3.080 million of current liabilities and US$8.212 million of shareholder equity. Reported working capital was positive US$4.617 million, while cash plus accounts receivable less current liabilities produced a narrower US$0.791 million quick-assets surplus.
Nine-month revenue rose 12.03% to US$16.211 million, but operating loss widened to US$2.218 million, a negative 13.68% operating margin. Operating cash outflow less capital spending was negative US$2.166 million—102.24% of June cash. Preferred issuance and the equity line supplied US$1.966 million of financing cash, offsetting 90.80% of that burn. The business therefore remained dependent on external financing despite reported growth and positive working capital.
Capital structure and acquisition risks
Common shares increased 25.66%, from 8.917 million in September 2025 to 11.205 million by August 13, 2026. Series B and C preferred shares carry 10% dividends, conversion-price resets, future-financing protections and senior liquidation rights, preventing certification of a current fully diluted common-equity denominator from the reviewed filing.
Bluebird consideration included 425,000 restricted common shares plus up to 525,000 earnout shares. The maximum 950,000 shares equal 8.48% of the August common count. Bluebird contributed more than US$0.5 million of Q3 revenue, but stand-alone normalized cash earnings were not disclosed.
The proposed Twinlab acquisition remained conditional on court approval and other closing requirements. Initial consideration includes approximately US$1.750 million of assumed secured debt and 2.230 million common shares, with additional assumed liabilities. Those shares equal 19.90% of the August count and 16.60% immediately after issuance on that base; the amount may increase to maintain the negotiated ownership percentage.
CIN conclusion
NotRated; no independently verified price target. Revenue growth has not yet translated into self-funded operating economics, while preferred protections, equity-line issuance and acquisition consideration leave common ownership path-dependent. A rating or target requires completed Twinlab filings, audited or pro-forma acquired financials, a complete assumed-liability and integration-cost schedule, post-close cash and debt, current preferred-conversion terms, the equity-line draw ledger, Bluebird earnout performance and a compatible dated quote. Rating, target, reference quote and upside remain null. This is a concise initial review, not a completed full valuation underwrite.
Sources: June Form 10-Q; Q3 results; Twinlab Form 8-K; Twinlab announcement; Bluebird announcement.
GrowGeneration · Nasdaq: GRWG
GrowGeneration
Status: NotRated. GrowGeneration Corp. is the Nasdaq-listed GRWG supplier serving cannabis-cultivation customers while also operating storage-solutions activities across other end markets. That mix matters: consolidated sales should not be valued as if they were entirely cannabis-operator revenue. The latest preserved evidence is the company’s June 30, 2026 Form 10-Q, its August outlook and its October 8 Order Junky acquisition announcement.
The June quarter filing reported US$23.460 million of cash and US$17.553 million of marketable securities, all corporate bonds. Against US$25.611 million of current liabilities, that produced a mechanical US$15.402 million liquidity surplus. The bonds are fair-value securities, however, not automatically unrestricted cash; current credit concentration, sale constraints and cash restrictions still require verification.
Liquidity also moved in the wrong direction. Cash plus securities fell US$5.051 million from December. The preserved model reconciles that decline exactly to negative US$4.107 million of first-half operating cash flow, US$0.283 million of capital spending, US$0.102 million of asset-disposal proceeds, US$1.010 million of repurchases, US$0.051 million of payroll-tax share withholding and a positive US$0.298 million securities fair-value change. Operating cash flow less capex was negative US$4.390 million. Doubling that figure gives a negative US$8.780 million historical annualized diagnostic, not a forecast.
Capital allocation adds another tension. The remaining US$9.0 million repurchase authorization equaled 21.94% of June cash plus securities. The 724,927 repurchased shares were 1.22% of June common shares. At the same time, 854,584 nonvested restricted stock units equaled 1.43% of June common shares, while the EPS note excluded 1.1 million antidilutive RSUs, or 1.85%. Those are different scopes and cannot be substituted for a current fully diluted denominator.
The Order Junky announcement says GrowGeneration acquired certain digital B2B assets and plans commercial deployment in 2027. It does not disclose consideration, payment form, assumed liabilities, earn-outs or the integration budget. A bounded review of the issuer’s SEC filing index through October 24 did not locate an agreement or acquisition filing; that is not an exhaustive regulator-database absence conclusion.
The investment case therefore remains held. Evidence of proprietary-brand growth, repeat consumable demand and successful integration could improve recurring economics. Continued cash use, weaker margins, receivable losses or acquisition leakage would undermine it. A current quote, post-June liquidity and repurchase bridge, transaction economics, award registry, and calibrated maintenance, software and integration spending are still needed. Rating, target price, reference quote and upside remain null, and this initial review is not a completed valuation underwrite.